Jihad Mustapha, MD
Cardiovascular Disease · Grand Rapids, MINPI 1316938723
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (40.5%), consulting fees and royalties or licence payments — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 41.7% of the total. Reporting peaked in 2021 at $689,082 and has fallen 91.1% since, to $61,525 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 564 payments — averaging $2820.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$663K
- Asahi Intecc CO., LTD.$355K
- Cardio Flow, Inc.$123K
- Cardiovascular Systems Inc.$114K
- Angiodynamics, Inc.$65K
- Terumo Medical Corporation$56K
- plus $214K from 33 others
Across 53 payments — averaging $3428.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$111K
- Terumo Medical Corporation$60K
- Endologix LLC$8K
- Medtronic$2K
- Bard Peripheral Vascular, Inc.$563
Across 13 payments — averaging $6840.56 each. An ownership or investment interest held by the physician or an immediate family member.
- Corvista Health, Inc.$89K
- Verge Medical, Inc.$380
- Vantis Vascular, Inc.$0
- Cardio Flow, Inc.$0
- Limflow Inc.$0
What the payments were for
- Royalty or licence$262,49517%
- Consulting fees$420,82526%
- Speaking & faculty fees$213,99513%
- Grants$25,0002%
- Travel & lodging$7,6660%
- Food & beverage$15,9891%
- Gifts$2630%
- Other$644,35741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ASAHI PTCA Guide Wire ASAHI Gladius Mongo 14$258,000
- Peripheral Orbital Atherectomy System$79,155
- Navicross$55,150
- Auryon Laser System 100-120 Vac$47,593
- GlideWire$43,277
- Diamondback Peripheral$38,340
- PERIPHERAL VASCULAR$36,695
- ASAHI Peripheral Guide Wires$36,000
- ASAHI PTCA Guide Wire$31,646
- Glidesheath$28,650
- GLIDESHEATH SLENDER$24,635
- VenaSeal$22,495
- IGT D Peripheral$18,400
- PERIPHERAL GUIDEWIRE$18,000
- Auryon Atherectomy Catheter$17,263
- CLINICAL TRIAL PRODUCT$16,463
- IN.PACT Admiral$13,751
- LIMFLOW SYSTEM$12,082
- LUTONIX$12,072
- XARELTO$11,200
How this compares
$1,590,589 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 68 | $68,884 |
| EliquisApixaban | 29 | $35,443 |
| ClopidogrelClopidogrel Bisulfate | 154 | $2,341 |
| Atorvastatin Calcium | 75 | $1,521 |
| Rosuvastatin Calcium | 46 | $909 |
| Ezetimibe | 17 | $334 |
| Metoprolol Succinate | 21 | $294 |
| Carvedilol | 14 | $188 |
| Methylprednisolone | 13 | $106 |
| Amlodipine Besylate | 15 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $106 | $68,88468 claims |
| PfizerEliquis | $141 | $35,44329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Grand Rapids
- Fadi SaabGrand Rapids$345K
- Harvinder SinghGrand Rapids$116K
- Chris JacobGrand Rapids$52K
- Marschall RungeAnn Arbor$1.8M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.